• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Committee pens letter to Mylan demanding EpiPen price info

October 4, 2016 By Sarah Faulkner

Committee pens letter to Mylan demanding EpiPen price infoMembers of the U.S. House Committee on Oversight & Government Reform penned a letter to Mylan (NSDQ:MYL) demanding a more complete look at the pricing of its EpiPen epinephrine auto-injector.

At a Sept. 21 congressional hearing, Mylan CEO Heather Bresch testified that the company makes a $100 profit per 2-pack of EpiPens. Last week, Mylan clarified that its operating profit is actually $166 before taxes and that the number it presented before the Senate reflects the U.S. statutory rate of 37.5%. Mylan’s overall tax rate is much lower, according to the Wall Street Journal.

The Canonsburg, Pa.-based company has been under fire since August, when reports revealed that it has raised the price of its EpiPen product by more than 500% since 2007. Bresch maintained that the problem stems from a system involving wholesalers, pharmacies, and pharmacy-benefit managers, who each take a cut of every prescription.

Oversight & Government Reform chairman Rep. Jason Chaffetz (R-Utah) and ranking member Rep. Elijah Cummings (D-Md.) wrote that Bresch’s testimony “omitted key tax assumptions that affect the company’s profit per pack” and “raises questions” about the company’s transparency.

The committee leaders wrote that they expect Mylan to provide all documents related to sales, profits, costs, manufacturing and distribution, Bresch’s notes for the congressional hearing, documents related to Mylan’s tax rates since 2007, and a comment on whether Mylan plans to try and extend market exclusivity for the EpiPen. The deadline for Mylan to respond with the requested information is Oct. 7.

“We remain committed to productive and continued cooperation with the committee, and we intend to respond to their request for additional information,” a Mylan spokesperson said, according to the Journal.

Mylan’s shares dropped -10% to $42.64 apiece when the criticism began in August. Since then, shares have slowly but steadily declined. The stock was trading at $37.46 per share in mid-morning activity today, down -1.1%.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured Tagged With: Capitol Hill, Mylan

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS